Name | Type | Posted | Actions |
|---|---|---|---|
https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=5503510&FileName=36C25020D0061-001.docx | LINK | May 15, 2020 |
6550--Agilent--Omnis-IHC Stainer
Contact and place of performance
Kellie Konopinski 734-222-4330 [email protected]
Not specified
VHAPM Part 806.3 Other Than Full and Open Competition (OFOC) SOP Attachment 2: Request for Sole Source Justification Format >SAT OFOC SOP Revision 08 Page 1 of 9 Original Date: 03/22/11 Revision 08 Date: 04/18/2018 DEPARTMENT OF VETERANS AFFAIRS Justification and Approval (J&A) For Other Than Full and Open Competition (>SAT) Acquisition Plan Action ID: 36C250-20-AP-1675 Contracting Activity: Department of Veterans Af...
View moreThe Department of Veterans Affairs, VISN 10, VA Ann Arbor Healthcare System, has issued a Justification and Approval for a sole-source procurement with Agilent Technologies, Inc. This requirement is for a firm-fixed-price, IDIQ cost-per-test contract to provide immunohistochemical patient specimen testing. The procurement includes the provision of one automated Dako Omnis immunohistochemical staining system, along with all necessary ancillary equipment, quality controls, slides, disposables, consumables, antibodies, reagents, and technical support. The anticipated period of performance runs from May 18, 2020, to May 17, 2023, consisting of one base year and two additional option years, with an estimated total value of $524,920.00.
The statutory authority for this non-competitive action is FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The VA Ann Arbor Healthcare System currently leases the Dako Omnis equipment, which requires proprietary reagents and supplies to ensure accurate results. The agency has invested significant professional and technical resources into the verification and validation of this specific system over the past two years. The polymer-based detection system utilized by this equipment provides faster staining protocols and higher specificity compared to alternative methods, resulting in more rapid diagnoses and operational cost savings.
This acquisition is classified under NAICS 325413 for In-Vitro Diagnostic Substance Manufacturing and PSC 6550 for In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. Market research, including an intent to sole source posted to Contract Opportunities, yielded no responses from other capable vendors or small business distributors. The contracting officer is Kellie Konopinski of the Network Contract Office 10, and the notice was published on May 15, 2020, under solicitation number 36C25020Q0350.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.